Avalo Therapeutics

About:

Avalo Therapeutics is a clinical-stage biopharmaceutical company.

Top Investors: OrbiMed, RA Capital Management, TCG Crossover, Deep Track Capital, Commodore Capital

Description:

Avalo Therapeutics is a clinical-stage biopharmaceutical company that employs a precision medicine approach to discover, develop, and commercialize highly targeted therapeutics in areas of significant unmet clinical need.

Total Funding Amount:

$232M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Rockville, Maryland, United States

Founded Date:

2011-01-01

Founders:

Isaac Blech

Number of Employees:

11-50

Last Funding Date:

2024-11-12

IPO Status:

Public

Industries: